FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200280246> ?p ?o ?g. }

• W4200280246 endingPage "46" @default.
• W4200280246 startingPage "36" @default.
• W4200280246 abstract "Introduction . The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the optimal drug sequence. Expansion of the arsenal of therapeutic possibilities and the use of new combinations will certainly improve the results of treatment of this category of patients and increase their life expectancy. Aim . We sought to describe treatment patterns of eribulin and clinical outcomes of metastatic HER2-positive breast cancer treated with eribulin plus trastuzumab combination in academic institutions and community oncology practices across the Russian Federation. Materials and methods . Patients treated with eribulin anytime between Jan, 2014 and Sep, 2019 with a diagnosis of MBC were identified by 23 providers from Russia. Providers retrospectively reviewed the health records and abstracted selected data points into an electronic case report form for each eligible patient. Results . 100 HER2-positive pts received eribulin in combination with trastuzumab. Median age was 55 (31–80) yrs and ECOG status 0–3. 67% pts had visceral metastases. Eribulin was administered as 1st and 2nd line to 23 (23%) pts, 3rd line to 31 (31%) pts, 4th line and later to 46 (46%). Median number of cycles was 5 (2–27). ORR was 12%, SD – 72%, SD > 6 months – 23%, PD – 16%. Clinical efficacy rate achieved in 35%. Median PFS was 5.07 months (95% CI 4.021–6.119). According to the ER-status the response to eribulin and trastuzumab was different. ORR was 18.8%, SD 72.9% in pts with ER-positive MBC (n = 48) and 5.8% and 71.2% respectively in ER-negative MBC (n = 52). Median PFS was 6.97 months (95% CI 3.924–10.016) in pts with ER-positive MBC and 4.67 months (95% CI 3.841–5.499) in ER-negative MBC (р = 0.3). The combination was well tolerated: dose reductions were required in 12% pts, withdrawal due to toxicity in 4% pts. The most common type of toxicity was hematological with neutropenia Gr III-IV in 14 (14%) pts. Peripheral neuropathy Gr III was observed in 5 (5%) pts. No cardiotoxicity was detected. Conclusions . This is the real-life data of clinical outcomes for patients receiving eribulin plus trastuzumab for HER2-positive MBC throughout the Russian Federation. Our experience with eribulin plus trastuzumab demonstrates that this combination may be a potential effective treatment option for HER-2 positive MBC patients." @default.
• W4200280246 created "2021-12-31" @default.
• W4200280246 creator A5001126969 @default.
• W4200280246 creator A5014840627 @default.
• W4200280246 creator A5016270046 @default.
• W4200280246 creator A5016431282 @default.
• W4200280246 creator A5019258474 @default.
• W4200280246 creator A5020552882 @default.
• W4200280246 creator A5022223386 @default.
• W4200280246 creator A5022911908 @default.
• W4200280246 creator A5024583613 @default.
• W4200280246 creator A5025307192 @default.
• W4200280246 creator A5034278890 @default.
• W4200280246 creator A5043961667 @default.
• W4200280246 creator A5046355491 @default.
• W4200280246 creator A5047057176 @default.
• W4200280246 creator A5050148763 @default.
• W4200280246 creator A5052477878 @default.
• W4200280246 creator A5053085042 @default.
• W4200280246 creator A5054416625 @default.
• W4200280246 creator A5056705823 @default.
• W4200280246 creator A5057152330 @default.
• W4200280246 creator A5059134154 @default.
• W4200280246 creator A5060461607 @default.
• W4200280246 creator A5060753407 @default.
• W4200280246 creator A5064507040 @default.
• W4200280246 creator A5071794777 @default.
• W4200280246 creator A5074223749 @default.
• W4200280246 creator A5076418700 @default.
• W4200280246 creator A5081523614 @default.
• W4200280246 creator A5089293877 @default.
• W4200280246 date "2021-12-08" @default.
• W4200280246 modified "2023-09-27" @default.
• W4200280246 title "Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study" @default.
• W4200280246 cites W1984007340 @default.
• W4200280246 cites W2010476765 @default.
• W4200280246 cites W2016027388 @default.
• W4200280246 cites W2029542561 @default.
• W4200280246 cites W2061860268 @default.
• W4200280246 cites W2106580933 @default.
• W4200280246 cites W2110444464 @default.
• W4200280246 cites W2120627364 @default.
• W4200280246 cites W2125550817 @default.
• W4200280246 cites W2132620319 @default.
• W4200280246 cites W2137228442 @default.
• W4200280246 cites W2137545466 @default.
• W4200280246 cites W2141393790 @default.
• W4200280246 cites W2159967578 @default.
• W4200280246 cites W2318605753 @default.
• W4200280246 cites W2387959609 @default.
• W4200280246 cites W2614773797 @default.
• W4200280246 cites W2810369514 @default.
• W4200280246 cites W2921016291 @default.
• W4200280246 cites W2944761827 @default.
• W4200280246 cites W2995808512 @default.
• W4200280246 cites W2995985965 @default.
• W4200280246 cites W2996630100 @default.
• W4200280246 cites W3015618437 @default.
• W4200280246 cites W4248292794 @default.
• W4200280246 doi "https://doi.org/10.21518/2079-701x-2021-20-36-46" @default.
• W4200280246 hasPublicationYear "2021" @default.
• W4200280246 type Work @default.
• W4200280246 citedByCount "0" @default.
• W4200280246 crossrefType "journal-article" @default.
• W4200280246 hasAuthorship W4200280246A5001126969 @default.
• W4200280246 hasAuthorship W4200280246A5014840627 @default.
• W4200280246 hasAuthorship W4200280246A5016270046 @default.
• W4200280246 hasAuthorship W4200280246A5016431282 @default.
• W4200280246 hasAuthorship W4200280246A5019258474 @default.
• W4200280246 hasAuthorship W4200280246A5020552882 @default.
• W4200280246 hasAuthorship W4200280246A5022223386 @default.
• W4200280246 hasAuthorship W4200280246A5022911908 @default.
• W4200280246 hasAuthorship W4200280246A5024583613 @default.
• W4200280246 hasAuthorship W4200280246A5025307192 @default.
• W4200280246 hasAuthorship W4200280246A5034278890 @default.
• W4200280246 hasAuthorship W4200280246A5043961667 @default.
• W4200280246 hasAuthorship W4200280246A5046355491 @default.
• W4200280246 hasAuthorship W4200280246A5047057176 @default.
• W4200280246 hasAuthorship W4200280246A5050148763 @default.
• W4200280246 hasAuthorship W4200280246A5052477878 @default.
• W4200280246 hasAuthorship W4200280246A5053085042 @default.
• W4200280246 hasAuthorship W4200280246A5054416625 @default.
• W4200280246 hasAuthorship W4200280246A5056705823 @default.
• W4200280246 hasAuthorship W4200280246A5057152330 @default.
• W4200280246 hasAuthorship W4200280246A5059134154 @default.
• W4200280246 hasAuthorship W4200280246A5060461607 @default.
• W4200280246 hasAuthorship W4200280246A5060753407 @default.
• W4200280246 hasAuthorship W4200280246A5064507040 @default.
• W4200280246 hasAuthorship W4200280246A5071794777 @default.
• W4200280246 hasAuthorship W4200280246A5074223749 @default.
• W4200280246 hasAuthorship W4200280246A5076418700 @default.
• W4200280246 hasAuthorship W4200280246A5081523614 @default.
• W4200280246 hasAuthorship W4200280246A5089293877 @default.
• W4200280246 hasBestOaLocation W42002802461 @default.
• W4200280246 hasConcept C121608353 @default.
• W4200280246 hasConcept C126322002 @default.
• W4200280246 hasConcept C143998085 @default.
• W4200280246 hasConcept C2775930923 @default.

• next